{"id":"linezolid-antimicrobial-lock-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Optic neuropathy"},{"rate":null,"effect":"Serotonin syndrome (with concurrent serotonergic agents)"}]},"_chembl":{"chemblId":"CHEMBL126","moleculeType":"Small molecule","molecularWeight":"337.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Linezolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits the initiation of protein synthesis. This bacteriostatic mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). When formulated as an antimicrobial-lock solution, it is instilled into central venous catheters to prevent biofilm formation and catheter-related bloodstream infections.","oneSentence":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:34:00.309Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of catheter-related bloodstream infections in central venous catheters"},{"name":"Treatment of biofilm-associated infections on indwelling catheters"}]},"trialDetails":[{"nctId":"NCT01592032","phase":"PHASE4","title":"Concentration of Antimicrobials in Catheter-lock Solutions","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-05","conditions":"Catheter-Related Infections, Bacteremia.","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["linezolid: zyloxid 2 mg/ml, 300 ml vial.","sodium heparin 1%, 5000 IU/5ml.","sodium chloride 0,9% 10 ml vial."],"phase":"marketed","status":"active","brandName":"Linezolid antimicrobial-lock solution","genericName":"Linezolid antimicrobial-lock solution","companyName":"Clinica Universidad de Navarra, Universidad de Navarra","companyId":"clinica-universidad-de-navarra-universidad-de-navarra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Prevention and treatment of central venous catheter-related bloodstream infections, Catheter lock therapy for hemodialysis and other central lines.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}